A randomized phase II study of concurrent cisplatin-radiotherapy with or without neoadjuvant chemotherapy using taxotere [docetaxel] and cisplatin in advanced nasopharyngeal carcinoma (NPC)
Latest Information Update: 21 Nov 2013
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary) ; Cisplatin
- Indications Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 21 Nov 2013
- 16 Nov 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 16 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.